Who is sponsoring NCT05204615?

NCT05204615 is sponsored by Adhera Health, Inc..

What drugs are being tested in NCT05204615?

Interventions in NCT05204615: Collection of clinical, psychometric and biometric data.

What condition does NCT05204615 study?

NCT05204615 studies Post-acute COVID-19 Syndrome.

Is NCT05204615 still recruiting?

NCT05204615 is currently completed. Last updated 5 January 2023.

Last reviewed 2023-01-05 · How we verify

NCT05204615: SENSING-AI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SENSING-AI Cohort for Long COVID Patients

Completed Last updated 5 January 2023

What this trial tests

trial testing Collection of clinical, psychometric and biometric data in Post-acute COVID-19 Syndrome in 10 participants. Completed in 28 April 2022.

Timeline

18 January 2022

Primary endpoint
12 February 2022

28 April 2022

Quick facts

Lead sponsor	Adhera Health, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	10
Start date	18 January 2022
Primary completion	12 February 2022
Estimated completion	28 April 2022
Sites	2 locations across Spain

Drugs / interventions tested

Collection of clinical, psychometric and biometric data

Conditions studied

Post-acute COVID-19 Syndrome — all drugs for Post-acute COVID-19 Syndrome →

Sponsor

Adhera Health, Inc. — full company profile →

Who can join

18 and older, any sex, with Post-acute COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prospective study will focus on the collection of biometric and psychometric data from a limited population for 1 month with the aim of complementing the SENSING-AI retrospective cohort.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

An Artificial Intelligence-Driven Digital Health Solution to Support Clinical Management of Patients With Long COVID-19: Protocol for a Prospective Multicenter Observational Study.
Fuster-Casanovas A, Fernandez-Luque L, Nuñez-Benjumea FJ, Moreno Conde A, et al · · 2022 · cited 4× · PMID 36166648 · DOI 10.2196/37704

Verify or expand the search:

Other Adhera Health, Inc. trials

Trials by the same sponsor.

NCT06999486 — Validation of a Computerised Adaptive Test for Measuring Caregiver Well-being · completed
NCT05631171 — Feasibility Study of Adhera® Fatigue Digital Program for Patients With Long COVID-related Fatigue · NA · completed
NCT05483803 — Digital Health Intervention for Caregivers Emotional and Self-management Support of Children With Type 1 Diabetes · NA · completed
NCT05483829 — Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients · NA · completed
NCT06247332 — SENSING-AI in Patients With Long COVID (SENSING-AI) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05204615 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Adhera Health, Inc.
Last refreshed: 5 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05204615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing